It was a busy week of approvals at the US FDA, which included the agency's nod to Novartis AG's multiple sclerosis (MS) drug Mayzent (siponimod) as the sixth novel drug approval of 2019.
But there was some interesting news in the non-novel arena as well. EMD Serono Inc.'s Mavenclad (cladribine) was also approved for MS
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?